Table 1 Clinicopathological characteristics of EOBC (< 40 years) and LOBC (≥ 40 years)
Age group 40 years | p-value | ||
|---|---|---|---|
< 40 | ≥ 40 | ||
Median (IQR) | 34.66 (5.55) | 54.29 (16.86) | |
Sex | |||
Male | 9 (1.80%) | 24 (1.20%) | 0.307 |
Female | 479 (98.20%) | 1906 (98.80%) | |
Total | 488 (100%) | 1930 (100%) | |
Biopsy type | |||
Incision biopsy | 29 (5.90%) | 128 (6.60%) | 0.437 |
Needle core biopsy | 372 (76.20%) | 1487 (77.00%) | |
Re-excision | 2 (0.40%) | 5 (0.30%) | |
Simple mastectomy/WLE | 34 (7.00%) | 120 (6.20%) | |
WLE/mastectomy + ALND | 38 (7.80%) | 143 (7.40%) | |
Other | 13 (2.70%) | 47 (2.40%) | |
Total | 488 (100%) | 1930 (100%) | |
Histological type of tumour major | |||
DCIS only | 22 (4.50%) | 51 (2.60%) | 0.096 |
Invasive carcinoma NST | 416 (85.20%) | 1708 (88.50%) | |
Lobular carcinoma | 18 (3.70%) | 42 (2.20%) | |
Mixed invasive carcinoma | 8 (1.60%) | 30 (1.60%) | |
Mucinous carcinoma | 15 (3.10%) | 52 (2.70%) | |
Other | 9 (1.80%) | 47 (2.40%) | |
Total | 488 (100%) | 1930 (100%) | |
Grade | |||
I | 90 (18.40%) | 297 (15.40%) | 0.539 |
II | 154 (31.60%) | 675 (35.00%) | |
III | 231 (47.30%) | 912 (47.30%) | |
Not assessable | 13 (2.70%) | 46 (2.40%) | |
Total | 488 (100%) | 1930 (100%) | |
LVI* | |||
Present | 75 (15.40%) | 295 (15.30%) | 0.897 |
Not identified | 403 (82.60%) | 1602 (83.00%) | |
Possible | 10 (2.00%) | 33 (1.70%) | |
Total | 488 (100%) | 1930 (100%) | |
PNI* | |||
Present | 8 (1.60%) | 69 (3.60%) | 0.03 |
Not identified | 480 (98.40%) | 1861 (96.40%) | |
Total | 488 (100%) | 1930 (100%) | |
DCIS | |||
Present | 121 (24.80%) | 416 (21.60%) | 0.124 |
Not present | 367 (75.20%) | 1514 (78.40%) | |
Total | 488 (100%) | 1930 (100%) | |
DCIS grade | |||
Low grade | 26 (21.50%) | 75 (18.00%) | 0.197 |
Intermediate | 59 (48.80%) | 192 (46.20%) | |
High grade | 36 (29.80%) | 149 (35.80%) | |
Total | 121 (100%) | 416 (100%) | |
Hormone receptor status | |||
Positive | 255 (52.30%) | 1075 (55.70%) | 0.172 |
Negative | 233 (47.70%) | 855 (44.30%) | |
Total | 488 (100%) | 1930 (100%) | |
Ki-67 group (20) | |||
< 20 | 86 (17.60%) | 381 (19.70%) | 0.29 |
> 20 | 402 (82.40%) | 1549 (80.30%) | |
Total | 488 (100%) | 1930 (100%) | |
Tumour size group | |||
< 2 cm | 10 (30.30%) | 30 (23.30%) | 0.913 |
2.0–5.0 cm | 14 (42.40%) | 71 (55.00%) | |
> 5.0 cm | 9 (27.30%) | 28 (21.70%) | |
Total | 33 (100%) | 129 (100%) | |
pT | |||
pT0 | 4 (10.50%) | 14 (9.90%) | 0.271 |
pTis (DCIS) | 4 (10.50%) | 6 (4.30%) | |
pTis (Paget) | 0 (0.00%) | 1 (0.70%) | |
pT1 | 10 (26.30%) | 38 (27.00%) | |
pT2 | 14 (36.80%) | 49 (34.80%) | |
pT3 | 4 (10.50%) | 17 (12.10%) | |
pT4 | 2 (5.30%) | 16 (11.30%) | |
Total | 38 (100%) | 141 (100%) | |
pN | |||
pN0 (i+) | 0 (0.00%) | 1 (0.80%) | 0.888 |
pN0 | 10 (34.50%) | 44 (36.10%) | |
pN1 | 10 (34.50%) | 33 (27.00%) | |
pN2 | 5 (17.20%) | 33 (27.00%) | |
pN3 | 4 (13.80%) | 11 (9.00%) | |
Total | 29 (100%) | 122 (100%) | |